New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
11:08 EDTKERX, BBY, WB, MACK, RMTI, SHLD, DB, ARUN, WUBA, AZNOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX WUBA ARUN DB SHLD RMTI MACK WB BBY AZN
News For KERX;WUBA;ARUN;DB;SHLD;RMTI;MACK;WB;BBY;AZN From The Last 14 Days
Check below for free stories on KERX;WUBA;ARUN;DB;SHLD;RMTI;MACK;WB;BBY;AZN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2014
08:25 EDTDBDeutsche ability to pass U.S. stress tests questioned after warning, FT says
Subscribe for More Information
08:20 EDTDBDeutsche Bank CFO faces internal criticism over reporting, WSJ says
U.S. authorities have expressed serious concerns about Deutsche Bank's financial data, it has recently come to light, but the bank's CFO Stefan Krause has also faced criticism from within the organization about the issues, say people familiar with the discussions, reported The Wall Street Journal. Reference Link
July 22, 2014
15:32 EDTDBNY Fed said Deutsche Bank U.S. unit reports 'inaccurate, unreliable,' WSJ says
Subscribe for More Information
09:47 EDTWBWeibo initiated with a Buy at Tigress Financial
Subscribe for More Information
07:31 EDTDBSenate Homeland Security & Government Affairs Committee to hold a hearing
Subscribe for More Information
05:25 EDTAZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
July 21, 2014
10:45 EDTBBYAnalysts roll out coverage on GoPro with differing views
Shares of GoPro (GPRO) are climbing after a number of analysts initiated coverage of the stock with different outlooks. GoPro develops mountable and wearable cameras. BULLISH TAKE: JPMorgan analyst Paul Coster initiated coverage of GoPro with an Overweight rating. GoPro is gaining share in the digital camcorder market, and it has begun to penetrate "active lifestyle" markets, which are a much larger opportunity for the company, Coster believes. The company could ship 10M of its products for use by active lifestyle participants annually, the analyst estimated. In a best case scenario, the company could also sell low-cost devices for the mass market, according to Coster. However, GoPro will face competition from major companies, including Google (GOOG) and possibly Apple (AAPL) in this market, warned Coster, who set a $51 price target on GoPro. Also initiating coverage of the name with an Overweight rating was Piper Jaffray analyst Sean Naughton. GoPro is in the early stages of growth, as the company's user base is poised to expand beyond extreme sports enthusiasts, the analyst forecast. The company has a competitive advantage over other brands, which should enable it to maintain strong profitability, added Naughton, who set a $48 price target on the shares. BEARISH TAKE: Stifel analyst Jim Duffy started coverage of GoPro with a Hold rating. The company's three year growth outlook is compelling, but the stock is fully valued, the analyst believes. The company faces a number of risks, including competition in the image device market and the possibility that its relationship with key channel partners, including Best Buy (BBY), could be disrupted, the analyst wrote. Sales to Best Buy accounted for 17% of GoPro's revenue in fiscal 2013, Duffy reported. After GoPro surged following its initial public offering, the stock is likely to advance by only limited amounts, wrote Barcalys analyst Joseph Wolf, who initiated coverage of the shares with an Equal Weight rating. The stock could fall to $30 if the company is unable to increase its hardware sales or make progress in its efforts to develop a media business, the analyst warned. He set a $45 price target on the shares. PRICE ACTION: A total of seven analysts rolled out coverage today on GoPro, according to The Flyís research, with only two recommending the stock with buy-equivalent ratings. Shares of the camera marker are up 3%, or $1.10, to $42.53 in morning trading.
July 18, 2014
06:26 EDTDBMetro hires Deutsche to guide on consumer-electronics unit, Bloomberg says
Metro (MTTRY) hired Deutsche Bank (DB) to examine options for its consumer-electronics unit, according to Bloomberg, citing two people with direct knowledge of the matter. The sources said that alternatives may include a sale, spinoff or IPO of the Media-Saturn division. Reference Link
July 16, 2014
17:22 EDTARUNAruba Networks initiated with a Neutral at Buckingham
Subscribe for More Information
12:22 EDTBBYBest Buy calls active on speculation of an activist investor stake
Subscribe for More Information
10:36 EDTAZNTreasury calls on Congress to halt inversion deals
Subscribe for More Information
10:24 EDTBBYRumor: Best Buy moves up on speculation of an activist investor stake
Subscribe for More Information
08:25 EDTDBCNBC / Institutional Investor to host a conference
Subscribe for More Information
08:01 EDTAZNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information
07:59 EDTAZNTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
July 15, 2014
10:28 EDTKERXHigh option volume stocks
High option volume stocks: TRGT ALB UUP ADHD ROC WWW CTRL KERX IMGN NI
July 14, 2014
10:00 EDTARUNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:05 EDTARUNAruba Networks upgraded to Outperform from Neutral at Macquarie
July 11, 2014
14:15 EDTARUNRuckus, Aruba advance after FCC approves new school WiFi program
Shares of Ruckus Wireless (RKUS) and Aruba Networks (ARUN) are rising after the FCC announced that it would allocate new funds to subsidize the launch of WiFi networks in schools and libraries. Ruckus and Aruba provide products used for WiFi networks. WHAT'S NEW: The FCC said it would allocate $2B over the next two years to subsidize the launch of WiFi connections at schools and libraries. For the following three years, the agency said it would look to spend $1B annually on the project. The FCC said the funds would be "distributed fairly to all schools and libraries while recognizing the needs of the nationís rural and poorest school districts." PRICE ACTION: In mid-afternoon trading, Ruckus surged 5.5% to $11.62 and Aruba advanced 4.6% to $17.04.
06:16 EDTBBYBest Buy price target raised to $36 from $31 at Citigroup
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use